S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:GNFT

Genfit Stock Forecast, Price & News

$3.35
+0.02 (+0.60%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.32
$3.37
50-Day Range
$3.34
$3.98
52-Week Range
$3.30
$7.19
Volume
6,210 shs
Average Volume
78,886 shs
Market Capitalization
$153.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.18
30 days | 90 days | 365 days | Advanced Chart
Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.


Genfit logo

About Genfit

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Headlines

Genfit (NASDAQ:GNFT) Stock Price Down 1.6%
November 17, 2021 |  americanbankingnews.com
GENFIT: Third Quarter 2021 Financial Information
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNFT
Fax
N/A
Employees
130
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.86 million
Book Value
($0.49) per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$153.53 million
Optionable
Not Optionable

Company Calendar

Today
11/27/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

1018th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

156th out of 201 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Genfit (NASDAQ:GNFT) Frequently Asked Questions

Is Genfit a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Genfit stock.
View analyst ratings for Genfit
or view top-rated stocks.

How has Genfit's stock been impacted by COVID-19 (Coronavirus)?

Genfit's stock was trading at $14.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNFT shares have decreased by 76.5% and is now trading at $3.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GNFT?

3 brokers have issued twelve-month price targets for Genfit's stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Genfit's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 228.4% from the stock's current price.
View analysts' price targets for Genfit
or view top-rated stocks among Wall Street analysts.

Who are Genfit's key executives?

Genfit's management team includes the following people:
  • Pascal Prigent, CEO & EVP-Marketing & Development
  • Dean W. Hum, Chief Operating Officer
  • Thomas Baetz, Chief Financial Officer
  • Carol L. Addy, Chief Medical Officer
  • Stefanie Magner, Chief Compliance Officer

What is Jean-François Mouney's approval rating as Genfit's CEO?

3 employees have rated Genfit CEO Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among Genfit's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?

When did Genfit IPO?

(GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is Genfit's stock symbol?

Genfit trades on the NASDAQ under the ticker symbol "GNFT."

Who are Genfit's major shareholders?

Genfit's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.69%) and Citadel Advisors LLC (0.05%).

Which institutional investors are selling Genfit stock?

GNFT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, and Citadel Advisors LLC.

How do I buy shares of Genfit?

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genfit's stock price today?

One share of GNFT stock can currently be purchased for approximately $3.35.

How much money does Genfit make?

Genfit has a market capitalization of $153.53 million and generates $8.86 million in revenue each year.

How many employees does Genfit have?

Genfit employs 130 workers across the globe.

What is Genfit's official website?

The official website for Genfit is www.genfit.com.

Where are Genfit's headquarters?

Genfit is headquartered at PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120.

How can I contact Genfit?

Genfit's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at (332) 016-4000 or via email at [email protected].


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.